Window to control monkeypox may be closing in US | CIDRAP

In other testing news, Sonic Healthcare of Austin, Texas, is the fifth commercial lab to offer the the Centers for Disease Control and Prevention’s (CDC’s) non-variola orthopoxvirus, high-complexity NAAT polymerase chain reaction assay, or monkeypox test.

The Biden administration announced earlier this month that public partnerships with labs would increase testing capacity quickly across the country.

The federal government also announced another big purchase of Jynneos, the monkeypox vaccine, late last week. The Department of Health and Human Services (HHS) said an additional 2.5 million doses would be entered into the Strategic National Stockpile (SNS) in early 2023.

The purchase brings the federal government’s available supply of vaccine to treat monkeypox to nearly 7 million doses by mid-2023.

Since late May, HHS has made more than 300,000 doses available to states and territories.

The European Union has secured 54,000 more doses of Jynneos. The union has so far delivered around 25,000 doses to six member states, according to Reuters.

Europe continues to be the epicenter of the monkeypox outbreak. Globally, there are 13,094 confirmed cases of the disease, with Spain (2,835), Germany (1,924), and the United Kingdom (1,856) reporting the highest case counts.

Source: Window to control monkeypox may be closing in US | CIDRAP